Skip to main content

Pharmala Biotech Holdings Inc.(MDMA-CN)
CSE

Today's Change
Delayed Last Update

PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA

Newswire.ca - Wed Aug 17, 2022

PharmAla's GMP LaNeo™ MDMA has completed all release testing, is ready for export

VANCOUVER, BC, Aug. 17, 2022 /CNW/ - PharmAla Biotech (CSE: MDMA) (the 'Company') has achieved a historic milestone: it is currently the only publicly-traded company to have produced GMP MDMA at scale. The company believes that it is currently the only source for commercially-available GMP MDMA other than the Multidisciplinary Association for Psychedelic Studies (MAPS). With the release of this large-scale batch of LaNeo™ MDMA Active Pharmaceutical Ingredient (API), PharmAla's GMP value-chain stands ready to support its clinical trial customers and partners globally.

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe